T
Takaomi Sanda
Researcher at National University of Singapore
Publications - 102
Citations - 7366
Takaomi Sanda is an academic researcher from National University of Singapore. The author has contributed to research in topics: Gene & Transcription factor. The author has an hindex of 35, co-authored 85 publications receiving 6257 citations. Previous affiliations of Takaomi Sanda include Boston Children's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George,Takaomi Sanda,Megan Hanna,Stefan Fröhling,William Luther,Jianming Zhang,Yebin Ahn,Wenjun Zhou,Wendy B. London,Patrick McGrady,Liquan Xue,Sergey Zozulya,Vlad Edward Gregor,Thomas R. Webb,Nathanael S. Gray,D. Gary Gilliland,Lisa Diller,Heidi Greulich,Stephan W. Morris,Matthew Meyerson,A. Thomas Look +20 more
TL;DR: In this paper, the authors reported the detection of previously unknown mutations in the ALK gene, which encodes a receptor tyrosine kinase, in 8% of primary neuroblastomas.
Journal ArticleDOI
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski,Tinghu Zhang,Peter B. Rahl,Brian J. Abraham,Jessica Reddy,Scott B. Ficarro,Anahita Dastur,Arnaud Amzallag,Sridhar Ramaswamy,Bethany Tesar,Catherine E. Jenkins,Nancy M. Hannett,Douglas W. McMillin,Takaomi Sanda,Taebo Sim,Nam Doo Kim,A. Thomas Look,Constantine S. Mitsiades,Andrew P. Weng,Jennifer R. Brown,Cyril H. Benes,Jarrod A. Marto,Richard A. Young,Nathanael S. Gray +23 more
TL;DR: The discovery and characterization of a covalent CDK7 inhibitor, THZ1, is presented, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity forCDK7.
Journal ArticleDOI
An Oncogenic Super-Enhancer Formed Through Somatic Mutation of a Noncoding Intergenic Element
Marc R. Mansour,Marc R. Mansour,Brian J. Abraham,Lars Anders,Alla Berezovskaya,Alejandro Gutierrez,Alejandro Gutierrez,Adam D. Durbin,Julia Etchin,Lee N. Lawton,Stephen E. Sallan,Stephen E. Sallan,Lewis B. Silverman,Lewis B. Silverman,Mignon L. Loh,Stephen P. Hunger,Takaomi Sanda,Richard A. Young,A. Thomas Look,A. Thomas Look +19 more
TL;DR: In this paper, the authors identify a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells in acute lymphoblastic leukemia (T-ALL) cases.
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski,Tinghu Zhang,Peter B. Rahl,Brian J. Abraham,Jessica Reddy,Scott B. Ficarro,Anahita Dastur,Arnaud Amzallag,Sridhar Ramaswamy,Bethany Tesar,Catherine E. Jenkins,Nancy M. Hannett,Douglas W. McMillin,Takaomi Sanda,Taebo Sim,Nam Doo Kim,A. Thomas Look,Constantine S. Mitsiades,Andrew P. Weng,Jennifer R. Brown,Cyril H. Benes,Jarrod A. Marto,Richard A. Young,Nathanael S. Gray +23 more
TL;DR: In this article, a covalent cyclin-dependent kinase inhibitor, THZ1, was proposed to target a remote cysteine residue located outside of the canonical kinase domain.
Journal ArticleDOI
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Alejandro Gutierrez,Alejandro Gutierrez,Takaomi Sanda,Ruta Grebliunaite,Arkaitz Carracedo,Leonardo Salmena,Yebin Ahn,Suzanne E. Dahlberg,Donna Neuberg,Lisa A. Moreau,Stuart S. Winter,Richard A. Larson,Jianhua Zhang,Alexei Protopopov,Lynda Chin,Pier Paolo Pandolfi,Lewis B. Silverman,Lewis B. Silverman,Stephen P. Hunger,Stephen E. Sallan,Stephen E. Sallan,A. Thomas Look,A. Thomas Look +22 more
TL;DR: Induction chemotherapy failed to induce remission in 3 of the 4 patients whose lymphoblasts harbored PTEN deletions at the time of diagnosis, compared with none of the 12 patients with mutations of PTEN exon 7, suggesting that PTEN deletion has more adverse therapeutic consequences than mutational disruptions that preserve the phosphatase domain.